PAMF Pulmonologist Performs First Robotic Bronchoscopy on a Patient in the U.S.
Procedure Advances Lung Cancer Diagnosis and Treatment
Mountain View, Calif. – Ganesh Krishna, M.D., director of interventional pulmonology at PAMF, part of the not-for-profit Sutter Health network, successfully performed an innovative robotic bronchoscopy procedure to view the inside of the lungs and obtain a tissue sample from a patient with an abnormal CT scan of the chest.
This procedure, the first of its kind performed in the United States, took place on March 30 at El Camino Hospital, as part of a clinical trial of Auris Health’s Monarch Platform.
“Since the robotic bronchoscope has the ability to travel deeper into the lung and precisely guide a biopsy instrument to even the most difficult nodules, the technology offers the potential to diagnose lung cancer at an earlier stage,” said Dr. Krishna, who is also medical director of the Interventional Pulmonology Program at El Camino Hospital and fellowship director of the Interventional Pulmonary Fellowship Program in collaboration with University of California, San Francisco (UCSF).
Krishna said that conventional bronchoscopy, used for many decades, is limited in how deeply it can search the lung and its complex system of airways. But he said the Monarch Platform incorporates small digital cameras that “allow us to peek into the lung directly and the robot gives us the stability to drive to the far reaches of the lung.”
Auris Health’s Monarch Platform has received approval from the U.S. Food and Drug Administration (FDA).
According to the American Cancer Society, lung cancer is the second most common cancer in both men and women and often the leading cause of cancer deaths in the United States, having a higher mortality rate than prostate, colon and breast cancers combined. Approximately 220,000 people are newly diagnosed with lung cancer each year and more than 155,000 people die from the disease annually in the United States.
The early and accurate diagnosis of lung cancer is critical. Today, 90 percent of people who have lung cancer die from the disease, in part because it is often not found until the cancer is at an advanced stage.